22nd Century Group Gross Profit 2011-2026 | XXII

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit 22nd Century Group

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
-	-	-	-	-	1.44 M	14.5 K	899 K	-708 K	-430 K	-581 K	30.6 K	6.82 M	-49.2 K	594 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
6.82 M	-708 K	803 K

Quarterly Gross Profit 22nd Century Group

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	287 K	225 K	-21.1 K	-86.3 K	-103 K	515 K	151 K	162 K	71.6 K	71.4 K	-340 K	-165 K	-274 K	-228 K	-185 K	-141 K	124 K	10.8 K	-281 K	-293 K	-16.4 K	-806	-241 K	2.94 K	270 K	-	32 K	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
515 K	-340 K	-17.5 K

Gross Profit of other stocks in the Biotechnology industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	-1.72 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	180 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	9.02 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	102 K	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	5.52 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	5.51 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	48.1 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1	-	-1.52 %	$ 24.7 M	USA
Compugen Ltd. CGEN	63.5 M	$ 2.66	0.38 %	$ 249 M	Israel
Abcam plc ABCM	270 M	-	-	$ 4.9 B	Britain
Midatech Pharma plc MTP	-428 K	-	-18.52 %	$ 27.3 M	Britain
Affimed N.V. AFMD	19.8 M	-	-34.95 %	$ 21.5 M	Germany
Институт стволовых клеток человека ISKJ	774 M	-	-	-	Russia
Celyad Oncology SA CYAD	5 K	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	53.8 M	-	-7.31 %	$ 87 M	USA
Ayala Pharmaceuticals AYLA	90 K	-	-	$ 7.46 M	Israel
Cyclacel Pharmaceuticals CYCCP	1.94 M	-	-4.36 %	$ 27 M	USA
Coherus BioSciences CHRS	339 M	$ 1.7	3.35 %	$ 199 M	USA
Anika Therapeutics ANIK	63.8 M	$ 14.71	-1.21 %	$ 211 M	USA
Celldex Therapeutics CLDX	5.48 M	$ 31.64	2.56 %	$ 2.1 B	USA
Advaxis ADXS	90 K	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	2.65 M	-	5.93 %	$ 314 M	Canada
CureVac N.V. CVAC	-10.6 M	-	-	$ 867 M	Germany
AIkido Pharma AIKI	10 K	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	2.03 M	$ 3.31	-3.88 %	$ 5.45 M	Israel
Aptinyx APTX	1.56 K	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	39.2 M	-	-0.23 %	$ 916 M	USA
Ampio Pharmaceuticals AMPE	-523 K	-	-11.43 %	$ 502 K	USA